The new projects bring the number of collaborations up to six and are related to clinical assets such as botensilimab, balstilimab, zalifrelimab, among others, Agenus said.
The partnerships are with companies that are developing drugs with complementary mechanisms to come up with immunotherapy combinations to treat tumors, the clinical-stage drugmaker said. The studies are sponsored and conducted by the collaborators while Agenus is providing the drugs and scientific support.
The stock was up about 8% in morning trading amid a broadly lower market.
Price: 1.74, Change: +0.13, Percent Change: +7.96
|Research Alert: CFRA Maintains Sell Opinion On Share...|
|Alphabet Results Likely to Be In Line With Estimates...|
|Oracle, Red Hat to Collaborate to Bring Red Hat Ente...|
|Insider Sell: Nucor|
|Aemetis Says New Pipeline, Two Biogas Digesters Oper...|